This database contains 168 studies, archived under the term: "adverse effects"
Click here to filter this large number of results.
Impact of smoking on cognitive decline in early old age: the Whitehall II cohort study
Sabia, Séverine,
Elbaz, Alexis,
Dugravot, Aline,
Head, Jenny,
Shipley, Martin,
Hagger-Johnson, Gareth,
Kivimaki, Mika,
Singh-Manoux, Archana
Context: Smoking is a possible risk factor for dementia, although its impact may have been underestimated in elderly populations because of the shorter life span of smokers.; Objective: To examine the association between smoking history and cognitive decline in the transition from midlife to old age.; Design: Cohort study.; Setting: The Whitehall II study. The […]
PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease
Rosas, H. D.,
Doros, G.,
Gevorkian, S.,
Malarick, K.,
Reuter, M.,
Coutu, J.-P.,
Triggs, T. D.,
Wilkens, P. J.,
Matson, W.,
Salat, D. H.,
Hersch, S. M.
Objective: To assess the safety and tolerability of high-dose creatine, the feasibility of enrolling premanifest and 50% at-risk subjects in a prevention trial, and the potential of cognitive, imaging, and blood markers.; Methods: Sixty-four eligible consenting participants were randomly allocated (1:1) to 15 g twice daily of creatine monohydrate or placebo for a 6-month double-blind […]
Galantamine treatment in outpatients with mild Alzheimer’s disease
Objective: To assess long-term effectiveness of galantamine in community-dwelling persons with mild Alzheimer’s disease.; Methods: Prospective open-label trial including patients with mild AD (NINCDS-ADRDA criteria) treated with galantamine for up to 36 months. Outcome parameters included ADAS-cog/11, Bayer-ADL scale (self- and caregivers’ ratings), 10-item NPI and CGI-change, safety and tolerability measures. Data are presented based […]
Insulin resistance and medial prefrontal gyrus metabolism in women receiving hormone therapy
Rasgon, Natalie L.,
Kenna, Heather A.,
Wroolie, Tonita E.,
Williams, Katherine E.,
DeMuth, Bevin N.,
Silverman, Daniel H. S.
Insulin resistance (IR) is a putative risk factor for cognitive decline and dementia, and has been shown to impede neuronal glucose metabolism in animal models. This post hoc study focused on metabolic changes in the medial prefrontal region, a brain region exhibiting decline years before documented cognitive changes, relative to high or low IR status […]
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial
Porsteinsson, Anton P.,
Drye, Lea T.,
Pollock, Bruce G.,
Devanand, D. P.,
Frangakis, Constantine,
Ismail, Zahinoor,
Marano, Christopher,
Meinert, Curtis L.,
Mintzer, Jacobo E.,
Munro, Cynthia A.,
Pelton, Gregory,
Rabins, Peter V.,
Rosenberg, Paul B.,
Schneider, Lon S.,
Shade, David M.,
Weintraub, Daniel,
Yesavage, Jerome,
Lyketsos, Constantine G.
Importance: Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory.; Objective: The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety, cognitive safety, […]
Plasma free choline, betaine and cognitive performance: the Hordaland Health Study
Nurk, Eha,
Refsum, Helga,
Bjelland, Ingvar,
Drevon, Christian A.,
Tell, Grethe S.,
Ueland, Per M.,
Vollset, Stein E.,
Engedal, Knut,
Nygaard, Harald A.,
Smith, David A.
Choline and betaine are nutrients involved in one-carbon metabolism. Choline is essential for neurodevelopment and brain function. We studied the associations between cognitive function and plasma concentrations of free choline and betaine. In a cross-sectional study, 2195 subjects (55 % women), aged 70-74 years, underwent extensive cognitive testing including the Kendrick Object Learning Test (KOLT), […]
The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer’s disease: a preliminary investigation
Nathan, Pradeep J.,
Boardley, Rebecca,
Scott, Nicola,
Berges, Alienor,
Maruff, Paul,
Sivananthan, Tharani,
Upton, Neil,
Lowy, Martin T.,
Nestor, Peter J.,
Lai, Robert
Background: The histamine H3 receptor plays a critical role in the negative neuromodulation of neurotransmitters involved in cognitive function. H3 receptor antagonists/inverse agonists have been shown to exert pro-cognitive effects in pre-clinical models. GSK239512 is a potent and selective H₃ receptor antagonist developed for the treatment of cognitive dysfunction in neurodegenerative disorders. In this study […]
Dopamine D₂-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer’s disease patients
Martorana, Alessandro,
Di Lorenzo, Francesco,
Esposito, Zaira,
Lo Giudice, Temistocle,
Bernardi, Giorgio,
Caltagirone, Carlo,
Koch, Giacomo
Dopamine is a neurotransmitter involved in several brain functions ranging from emotions control, movement organization to memory formation. It is also involved in the regulation of mechanisms of synaptic plasticity. However, its role in Alzheimer’s disease (AD) pathogenesis is still puzzling. Several recent line of research instead indicates a clear role for dopamine in both […]